Fate Therapeutics Company Insiders
| FATE Stock | USD 4.08 0.18 4.62% |
About 86 percent of Fate Therapeutics' insiders are activelly selling. The analysis of the overall insider sentiment regarding Fate Therapeutics suggests that quite a large number of insiders are panicking. Fate Therapeutics employs about 181 people. The company is managed by 12 executives with a total tenure of roughly 29 years, averaging almost 2.0 years of service per executive, having 15.08 employees per reported executive.
| Scott Wolchko CEO Founder, CEO and President and Director |
| Sarah Cooley President Senior Vice President - Clinical Translation |
Fate Therapeutics' Insider Buying Vs Selling
14
Selling | Buying |
Latest Trades
| 2024-01-29 | Edward J Dulac III | Disposed 1849 @ 5 | View | ||
| 2024-01-09 | J Scott Wolchko | Disposed 14391 @ 4.37 | View | ||
| 2023-12-26 | Redmile Group, Llc | Acquired 44630 @ 3.72 | View | ||
| 2023-08-18 | Edward J Dulac III | Disposed 4718 @ 2.8 | View | ||
| 2023-08-04 | Yuan Xu | Disposed 632 @ 3.71 | View | ||
| 2023-07-05 | Edward J Dulac III | Disposed 5182 @ 4.83 | View | ||
| 2023-06-14 | Yuan Xu | Disposed 3460 @ 5.58 | View |
Monitoring Fate Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Fate |
Fate Therapeutics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Fate Therapeutics' future performance. Based on our forecasts, it is anticipated that Fate will maintain a workforce of about 180 employees by June 2024.Fate Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.2084) % which means that it has lost $0.2084 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4207) %, meaning that it created substantial loss on money invested by shareholders. Fate Therapeutics' management efficiency ratios could be used to measure how well Fate Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of May 12, 2024, Return On Tangible Assets is expected to decline to -0.33. In addition to that, Return On Capital Employed is expected to decline to -0.4. At present, Fate Therapeutics' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 584.4 M, whereas Non Currrent Assets Other are forecasted to decline to 8,549.As of May 12, 2024, Common Stock Shares Outstanding is expected to decline to about 54.2 M. The current year's Net Loss is expected to grow to about (240.9 M)
Fate Therapeutics Workforce Comparison
Fate Therapeutics is rated below average in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 4,702. Fate Therapeutics holds roughly 181 in number of employees claiming about 4% of equities under Health Care industry.
Fate Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Fate Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Fate Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Fate Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-03-01 | 0.5714 | 4 | 7 | 1,800,000 | 53,042 |
| 2023-12-01 | 0.6667 | 2 | 3 | 1,700,000 | 1,681,318 |
| 2023-06-01 | 2.0 | 18 | 9 | 7,012,641 | 6,484,869 |
| 2023-03-01 | 2.0 | 12 | 6 | 2,832,447 | 86,951 |
| 2022-09-01 | 0.3 | 3 | 10 | 25,000 | 68,023 |
| 2022-06-01 | 1.6 | 24 | 15 | 306,916 | 149,830 |
| 2022-03-01 | 0.4474 | 17 | 38 | 897,765 | 435,904 |
| 2021-12-01 | 0.5714 | 16 | 28 | 590,366 | 330,414 |
| 2021-09-01 | 0.3529 | 12 | 34 | 190,104 | 376,710 |
| 2021-06-01 | 1.1154 | 29 | 26 | 254,635 | 273,275 |
| 2021-03-01 | 0.2329 | 17 | 73 | 853,951 | 637,207 |
| 2020-12-01 | 0.2895 | 11 | 38 | 240,000 | 485,154 |
| 2020-09-01 | 0.4444 | 4 | 9 | 225,000 | 75,000 |
| 2020-03-01 | 1.5 | 12 | 8 | 713,075 | 125,175 |
| 2019-12-01 | 0.1818 | 2 | 11 | 50,000 | 199,217 |
| 2019-09-01 | 0.0714 | 3 | 42 | 906,143 | 383,403 |
| 2019-06-01 | 1.1538 | 15 | 13 | 174,940 | 93,670 |
| 2019-03-01 | 0.5313 | 17 | 32 | 1,421,500 | 562,920 |
| 2018-09-01 | 0.5 | 5 | 10 | 4,353,704 | 595,196 |
| 2018-06-01 | 3.5 | 7 | 2 | 101,054 | 21,054 |
| 2016-09-01 | 1.0 | 1 | 1 | 2,570 | 2,570 |
| 2016-06-01 | 8.0 | 8 | 1 | 359,090 | 0.00 |
| 2016-03-01 | 5.5 | 11 | 2 | 771,540 | 7,500 |
| 2015-12-01 | 0.8571 | 6 | 7 | 352,250 | 162,338 |
| 2015-06-01 | 3.3333 | 10 | 3 | 103,000 | 33,000 |
| 2014-06-01 | 0.8261 | 19 | 23 | 101,645 | 81,468 |
| 2014-03-01 | 1.0 | 6 | 6 | 460,000 | 27,326 |
| 2013-12-01 | 3.1176 | 53 | 17 | 13,965,402 | 4,237,538 |
Fate Therapeutics Notable Stakeholders
A Fate Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Fate Therapeutics often face trade-offs trying to please all of them. Fate Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Fate Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Scott Wolchko | Founder, CEO and President and Director | Profile | |
| Sarah Cooley | Senior Vice President - Clinical Translation | Profile | |
| Barbara Hickingbottom | Senior Development | Profile | |
| Jim MBA | Senior Development | Profile | |
| MS MBA | Chief Officer | Profile | |
| Cindy JD | Corporate Counsel | Profile | |
| Jerome Bressi | Senior Quality | Profile | |
| YuWaye MD | Chief Officer | Profile | |
| Mark DVM | Chief Officer | Profile | |
| Cindy Tahl | General Secretary | Profile | |
| Edward III | Chief Officer | Profile | |
| Bahram Valamehr | Chief Development Officer | Profile |
About Fate Therapeutics Management Performance
The success or failure of an entity such as Fate Therapeutics often depends on how effective the management is. Fate Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Fate management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Fate management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.32) | (0.33) | |
| Return On Capital Employed | (0.38) | (0.40) | |
| Return On Assets | (0.32) | (0.33) | |
| Return On Equity | (0.44) | (0.46) |
The data published in Fate Therapeutics' official financial statements usually reflect Fate Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Fate Therapeutics. For example, before you start analyzing numbers published by Fate accountants, it's critical to develop an understanding of what Fate Therapeutics' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Fate Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Fate Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Fate Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Fate Therapeutics. Please utilize our Beneish M Score to check the likelihood of Fate Therapeutics' management manipulating its earnings.
Fate Therapeutics Workforce Analysis
Traditionally, organizations such as Fate Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Fate Therapeutics within its industry.Fate Therapeutics Manpower Efficiency
Return on Fate Therapeutics Manpower
| Revenue Per Employee | 351K | |
| Revenue Per Executive | 5.3M | |
| Net Loss Per Employee | 889.1K | |
| Net Loss Per Executive | 13.4M | |
| Working Capital Per Employee | 1.6M | |
| Working Capital Per Executive | 24.4M |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fate Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Complementary Tools for Fate Stock analysis
When running Fate Therapeutics' price analysis, check to measure Fate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fate Therapeutics is operating at the current time. Most of Fate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fate Therapeutics' price. Additionally, you may evaluate how the addition of Fate Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |
Is Fate Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fate Therapeutics. If investors know Fate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.64) | Revenue Per Share 0.065 | Quarterly Revenue Growth (0.97) | Return On Assets (0.21) | Return On Equity (0.42) |
The market value of Fate Therapeutics is measured differently than its book value, which is the value of Fate that is recorded on the company's balance sheet. Investors also form their own opinion of Fate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fate Therapeutics' market value can be influenced by many factors that don't directly affect Fate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.